FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER (HER2+BC) PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS

被引：0
作者：
Bellone, M. [1 ]
Pradelli, L. [1 ]
Sanfilippo, A. [1 ]
Caputo, A. [2 ]
Manevy, M. [3 ]
Zerilli, A. [4 ]
机构：
[1] AdRes HEOR, Turin, TO, Italy
[2] Roche Spa, Monza, Italy
[3] F Hoffmann La Roche Ltd, Delemont, Switzerland
[4] Roche Spa, Milan, MI, Italy
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC113
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [31] HOSPITAL CAPACITY TOOL TO ASSESS THE POTENTIAL IMPACT OF USING A FIXED DOSE COMBINATION OF PERTUZUMAB/TRASTUZUMAB FOR SUBCUTANEOUS INJECTION VERSUS INTRAVENOUS PERTUZUMAB/ TRASTUZUMAB IN HER2+BREAST CANCER
    Cunha, A.
    VALUE IN HEALTH, 2023, 26 (12) : S296 - S296
  • [32] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Young-A Heo
    Yahiya Y. Syed
    Targeted Oncology, 2019, 14 : 749 - 758
  • [33] Pertuzumab plus trastuzumab increases survival in patients with HER2-positive breast cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (11) : 611 - 611
  • [34] First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
    Araki, Kazuhiro
    Fukada, Ippei
    Yanagi, Hiroyo
    Kobayashi, Kokoro
    Shibayama, Tomoko
    Horii, Rie
    Takahashi, Shunji
    Akiyama, Futoshi
    Ohno, Shinji
    Ito, Yoshinori
    BREAST, 2017, 35 : 78 - 84
  • [35] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
  • [36] The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis
    Wu, Yi-Ying
    Huang, Tzu-Chuan
    Tsai, Tsung-Neng
    Chen, Jia-Hong
    Dai, Ming-Shen
    Chang, Ping-Ying
    Ho, Ching-Liang
    Ye, Ren-Hua
    Chung, Tsai-Rong
    Chen, Yeu-Chin
    Chao, Tsu-Yi
    PLOS ONE, 2016, 11 (03):
  • [37] Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China
    Chai, Qingqing
    Wen, Haini
    Lang, Yitian
    Zhang, Lingyu
    Song, Yan
    Liu, Xiaoyan
    CLINICAL DRUG INVESTIGATION, 2022, 42 (11) : 937 - 947
  • [38] Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China
    Qingqing Chai
    Haini Wen
    Yitian Lang
    Lingyu Zhang
    Yan Song
    Xiaoyan Liu
    Clinical Drug Investigation, 2022, 42 : 937 - 947
  • [39] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Kerry Dwan
    Rumona Dickson
    Chris Proudlove
    Yenal Dundar
    PharmacoEconomics, 2015, 33 : 13 - 23
  • [40] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
12345